First, the analysis of a series of 28 HER2-positive tumours in the discovery series, treated with the neoadjuvant setting revealed an association between GSDMB amplification and the lack of pathologic complete response (pCR) (p = 0.001, Table 2a). Here, ERBB2 is linked to neoplasm.